Study of a new cell therapy for B-cell lymphoma that has returned
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy (called RJMty19) for people with B-cell lymphoma that has returned or not responded to standard treatments. The therapy aims to find and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of B-cell lymphoma that is CD19-positive (a marker on the cancer cells).
- Your lymphoma has come back or has not responded to at least two lines of standard treatment.
- You have previously received rituximab (or similar) and chemotherapy.
- You are able to take care of yourself (ECOG 0-1).
- You have at least one measurable tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This early trial tests a new type of cell therapy (called ARI0003) for aggressive B-cell lymphomas that have not responded to standard treatments or have relapsed. The therapy uses your own immune cells to fight the cancer, and it may offer a new option when other treatments have not worked well.
Hear when a new B-cell Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.